The FDA updated prescribing information on labels of cholesterol-lowering statins to include alerts about the risk of increased blood glucose levels, diabetes, memory loss and other health problems. The change was based on a review of medical literature and adverse-event reports. "The value of statins in preventing heart disease has been clearly established," said FDA official Dr. Amy G. Egan. "Their benefit is indisputable, but they need to be taken with care and knowledge of their side effects."
FDA strengthens warning labels on cholesterol-lowering statins
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||